SK-BR-3 is a human breast cancer cell line that overexpresses the Her2 (Neu/ErbB-2) gene product. These cells display an epithelial morphology in tissue culture and are capable of forming poorly differentiated tumors in immunocompromised mice. The SK-BR-3 cells and products derived from it are used often as positive controls in assays for Her2. In addition, the cell line is also a useful preclinical model to screen for therapeutic agents targeting Her2 and to delineate mechanisms of resistance to Her2-targeted therapies.
This cell line was established in 1970 from the pleural effusion of a 43-year-old Caucasian female with malignant adenocarcinoma of the breast.
- Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
- Germain Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
This cell line may be licensed nonexclusively for research or commercial purposes.
For internal research purposes by a commercial entity: Utilize MSK’s Express License, attached here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.
To proceed, please download this contract, fill in all relevant fields, and email a scanned version to [email protected]. Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.
For licensing requests for a commercial purpose: Contact MSK’s Tangible Materials team at [email protected].
For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, [email protected].